CClinicalTrials.gg
CompletedNCT02200679Updated May 16, 2017

National Study on Autism Spectrum Disorder in China

An observational study in Autism Spectrum Disorders, sponsored by Fudan University. Completed at 8 sites in China. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2017-05-16.

Sponsored by Fudan University · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
143,755
Ages
6 Years to 12 Years
Sex
All
01

Study summary

The aims of the national population-based study on Autism Spectrum Disorder (ASD) include: (1) to understand the overall prevalence of ASD in children aged 6-12 years in 8 cities (n=120,000), (2) to explore environmental and genetic risk factors associated with ASD

Read the detailed description

The study is a multicenter, cross-sectional study involing eight cities. The program includes a prevalence study and a risk factors analysis.

  1. Prevalence study on ASD To estimate the national prevalence of ASD in Chinese pediatric population aged 6-12 years.

    1.1. Target population This 4-year study is initiated in the year of 2013 in eight cities of China . For each city, 3 communities with different economic levels were chosen including all children born within Jan 2001 to Dec 2007 (ages 6-12 years at screening) with local residency or have lived in the community over 6 months. The ASD children who are attending special education schools and meet with the inclusion criteria will also be included in the prevalence estimation.

    1.2. Sample size Based on the previous regional studies , we plan to recruit approx.15, 000 subjects for each city (average. 5,000 subjects for each community), and 120,000 subjects in total then comprise the national study sample. The plan will be updated, based on the prevalence obtained in the pilot study.

    1.3. Screening and diagnosis The screening tool will be chosen from Autism Spectrum Rating Scale (ASRS) or SRS(Social Responsiveness Scale) after pilot study.The questionnaire is a parent-administered form that takes approximately 15-20 minutes to complete. Parents of recruied children were invited to complete the questionnaire. Parents of all questionnaire screen-positive children will be contacted for appointing further diagnostic evaluations. Children whose parents could not be reached are classified as non-responders. The DSM-Ⅳ, ADI-R and ADOS (ADI-R: Autism Diagnosis Interview-Revised, ADOS: Autism Diagnosis Observation Scales) are used for diagnostic evaluations. Co-morbidities, such as epilepsy and ADHD (Attention Deficit Hyperactivity Disorder )after aditional medical examinations such as, EEG(electroencephalogram), head circumference, anthropometrics, allergies, sleep patterns, etc.

  2. Risk Factors study on ASD A classic case-control design is applied to explore the risk factors of ASD. 2.1. Study subjects 2.1.1. Cases and control Cases were children living in target communities who are identified as positive based on questionnaire screen and the subsequent diagnosis with DSM-Ⅳ, ADOS and ADI-R.

Controls were children who are screened to be negative and matched to cases by age, gender, and class.

2.2. Environmental pollutants exposures Given the hypothesis that environmental factors might play a role in the etiology of ASD, we will analyze the biological samples of the subjects to investigate environmental exposures including chronic lead exposure, pesticides exposure, and endocrine disruptors exposure , for which, hair, blood, and urine will be collected for cases and controls. The detailed protocol for the measurement of each kind of biological sample has been introduced everywhere (see the references in individual block).

2.3. Analysis of other potential risk factors This study will also analyze the association between the onset of ASD and other risk factors, including diet (), living environment(),perinatal characteristics of parents, feeding history, baby growth and development after birth by using questionnaire and reviewing medical records.

2.4. Genetic analysis We are going to use the targeted area capture technology developed before and HiSeq2000, the second generation of high throughput sequencing platform, to carry out the molecular diagnosis screening (monogenic disease). Also, we will screen through Trio those ASD-related genetic mutations that are of high credibility and occur frequently so as to classify ASDs according to their definite etiologies.Furthermore, we will continue the study on the distribution of ASD relevant gene mutations among patients in China, which will lay a solid foundation for further studies of molecular epidemiology.Meanwhile, we will also apply genome-wide sequencing technology on the positive cases so as to find new mutation that might serve as potential molecular markers facilitating the diagnosis and treatment of ASDs.

A pilot study involving 4 cities (n=400 for each, in total n>=1600)will be conducted to test all methodology that will be applied in the prevalence study. A diagnostic study will be performed to evalute the performance of ASRS and SRS in screening ASD, one of which will be applied in the main study.

02

Conditions studied

  • Autism Spectrum Disorders

Keywords

  • Autism spectrum disorders
  • Prevalence
  • Diagnosis
  • Screen
  • Risk Factor
  • SRS
  • ASRS
03

In context

Autistic Disorder

1,344 studies on the registry are indexed under Autistic Disorder; 334 are open to participants now.

This study's enrollment of 143,755 is above the median of 102 across 267 observational studies indexed under Autistic Disorder.

Browse Autistic Disorder studies →

Lead sponsor

Fudan University is the lead sponsor of 1,270 studies on the registry; 623 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Community-based populations aged 6-12 years old form 8 cities in China

Inclusion criteria

  • All children aged 6-12 years old and have lived in the recruied community over 6 months.

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
143,755 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Autism Spectrum Disorders

    Cases were children living in target communities who are identified as positive based on questionnaire screen and the following diagnosis with DSM-Ⅳ, ADOS and ADI-R

06

What researchers measure

Primary outcomes

  1. prevalence of autism spectrum disorder

    The outcome of the study include ASD and its commorbidities. The disease occurs in children as early as 18 months old, however the confirmation of diagnosis usually is 3 or later. 6-12 years is time frame for confirmed diagnosis.

    Time frame: 3-12 years

Secondary outcomes

  1. ASRS

    ASRS is a measure for screen ASD.

    Time frame: 6-18 years

  2. ADI-R

    The ADI-R is a good diagnosis tool for children with ASD

    Time frame: 4-18 yeas

  3. ADOS

    The ADOS is a appropriate instrutment for ASD diagnosis.

    Time frame: 14months-16 years

07

Study locations

8 sites
  • Capital Institute of Pediatrics
    Beijing, Beijing, China
  • Children's Hospital of Chongqing Medical University
    Chongqing, Chongqing, China
  • The Third Affiliated Hosptial,Sun Yat-Sen University
    Guangzhou, Guangdong, China
  • Harbin Medical University
    Harbin, Heilongjiang, China
  • Central South University
    ChangSha, Hunan, China
  • Chengdu Women's and Children's Central Hospital
    Chengdu, Sichuan, China
  • Sichuan University
    Chengdu, Sichuan, China
  • The 2nd Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
08

References and documents

Publications

  • Yan W, Siegert RJ, Zhou H, Zou X, Wu L, Luo X, Li T, Huang Y, Guan H, Chen X, Mao M, Xia K, Zhang L, Li E, Li C, Zhang X, Zhou Y, Shih A, Fombonne E, Zheng Y, Han J, Sun Z, Jiang YH, Wang Y. Psychometric properties of the Chinese Parent Version of the Autism Spectrum Rating Scale: Rasch analysis. Autism. 2021 Oct;25(7):1872-1884. doi: 10.1177/13623613211004054. Epub 2021 Apr 12. PubMed 33845648 ↗
  • Zhou H, Zhang L, Wu L, Zou X, Luo X, Xia K, Wang Y, Xu X, Ge X, Sun C, Deng H, Fombonne E, Jiang YH, Yan W, Wang Y. Validity and reliability analysis of the Chinese parent version of the Autism Spectrum Rating Scale (6-18 years). Psychiatry Res. 2015 Dec 15;230(2):255-61. doi: 10.1016/j.psychres.2015.09.003. Epub 2015 Sep 8. PubMed 26384573 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02200679
Lead sponsor
Fudan University
Collaborators
National Health and Family Planning Commission, P.R.China
Responsible party
Yi Wang (Vice Prsident Chlidren's Hospital of Fudan University, Fudan University) — Principal investigator
First posted
Jul 25, 2014
Start date
Jan 2014
Primary completion
Dec 2016
Completion
Dec 2016
Last update
May 16, 2017

Study contacts

Yi Wang, PhD,MD
principal investigator · Children's Hospital of Fudan University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion